Sanofi said profit may drop this year as the French drugmaker pursues new drivers of growth to offset declines for its best-selling diabetes treatment Lantus. Sanofi expects earnings per share excluding some items to be stable to down as much as 3 percent at constant exchange rates, the Paris-based company said in a statement on Wednesday.